United States

Inhibrx (NASDAQ:INBX) unveils Sanofi deal along with financials

Article Image

Inhibrx (NASDAQ:INBX), a leading clinical-stage biopharmaceutical company, has unveiled significant developments, including its financial performance for the fiscal year ended December 31, 2023.

A pivotal move in the company's trajectory involves the definitive agreement with Aventis, a subsidiary of Sanofi, for the sale of INBRX-101.

This transaction will lead to the establishment of a new publicly traded entity, Inhibrx Biosciences.

Under the terms of the agreement, Sanofi will acquire all outstanding shares of Inhibrx, providing shareholders with $30 per share in cash, a contingent value right for a future payment, and a share of the new entity for every four shares of Inhibrx common stock held.

Additionally, Sanofi will assume Inhibrx's outstanding debt and infuse the new company with $200 million.

Financially, Inhibrx reported a decrease in cash and cash equivalents from $337.3 million to $277.9 million.

Research and development expenses surged to $82.1 million in the fourth quarter from $30.5 million in the same period the previous year.

General and administrative expenses also rose to $7.8 million in the fourth quarter of 2023, up from $5.3 million in 2022.

Meanwhile, the net loss for Q4 2023 widened to $93.6 million, or $1.73 per share, compared to $40.9 million, or $0.95 per share, in Q4 2022.

Disclaimer

Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

Publisher
Grafa